Skip to main content

Rabbit Polyclonal VGP antibody. Suitable for WB and reacts with Tag - Sudan ebolavirus, Recombinant full length protein - Zaire ebolavirus, Recombinant full length protein - Marburg virus, Recombinant full length protein - Sudan ebolavirus samples. Immunogen corresponding to Native Full Length Protein corresponding to Sudan ebolavirus - Uganda (2000) GP.

Be the first to review this product! Submit a review

Images

Western blot - Anti-SEBOV GP antibody (AB190653), expandable thumbnail

Key facts

Isotype
IgG
Host species
Rabbit
Storage buffer

Preservative: 0.01% Sodium azide
Constituents: 99% PBS

Form
Liquid
Clonality
Polyclonal

Immunogen

  • Native Full Length Protein corresponding to Sudan ebolavirus - Uganda (2000) GP. Database link Q7T9D9

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
WB
Marburg virus
Predicted
Recombinant full length protein - Marburg virus
Tested
Recombinant full length protein - Sudan ebolavirus
Tested
Recombinant full length protein - Zaire ebolavirus
Tested
Sudan ebolavirus
Predicted
Tag - Sudan ebolavirus
Tested
Zaire ebolavirus
Predicted

Tested
Tested

Species
Tag - Sudan ebolavirus
Dilution info
1-5 µg/mL
Notes

-

Species
Recombinant full length protein - Zaire ebolavirus
Dilution info
1-5 µg/mL
Notes

-

Species
Recombinant full length protein - Marburg virus
Dilution info
1/1 - 1/5
Notes

-

Species
Recombinant full length protein - Sudan ebolavirus
Dilution info
1/1 - 1/5
Notes

-

Predicted
Predicted

Species
Zaire ebolavirus, Marburg virus, Sudan ebolavirus
Dilution info
-
Notes

-

Target data

Function

Envelope glycoprotein. Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, down-regulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes. Down-regulates as well the function of host natural killer cells. Counteracts the antiviral effect of host BST2/tetherin that restricts release of progeny virions from infected cells. However, cooperates with VP40 and host BST2 to activate canonical NF-kappa-B pathway in a manner dependent on neddylation. Shed GP. Functions as a decoy for anti-GP1,2 antibodies thereby contributing to viral immune evasion. Interacts and activates host macrophages and dendritic cells inducing up-regulation of cytokine transcription. This effect is mediated throught activation of host TLR4. GP1. Responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into dendritic cells (DCs) and endothelial cells (By similarity). Binding to the macrophage specific lectin CLEC10A also seems to enhance virus infectivity (By similarity). Interaction with FOLR1/folate receptor alpha may be a cofactor for virus entry in some cell types, although results are contradictory (By similarity). Members of the Tyro3 receptor tyrosine kinase family also seem to be cell entry factors in filovirus infection (By similarity). Once attached, the virions are internalized through clathrin-dependent endocytosis and/or macropinocytosis. After internalization of the virus into the endosomes of the host cell, proteolysis of GP1 by two cysteine proteases, CTSB/cathepsin B and CTSL/cathepsin L removes the glycan cap and allows GP1 binding to the host entry receptor NPC1. NPC1-binding, Ca(2+) and acidic pH induce a conformational change of GP2, which unmasks its fusion peptide and permit membranes fusion (By similarity). GP2. Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induces an irreversible conformational change in GP2, releasing the fusion hydrophobic peptide.

Additional Targets

SEBOV GP

Alternative names

Recommended products

Rabbit Polyclonal VGP antibody. Suitable for WB and reacts with Tag - Sudan ebolavirus, Recombinant full length protein - Zaire ebolavirus, Recombinant full length protein - Marburg virus, Recombinant full length protein - Sudan ebolavirus samples. Immunogen corresponding to Native Full Length Protein corresponding to Sudan ebolavirus - Uganda (2000) GP.

Key facts

Isotype
IgG
Form
Liquid
Clonality
Polyclonal
Immunogen
  • Native Full Length Protein corresponding to Sudan ebolavirus - Uganda (2000) GP. Database link Q7T9D9
Purification technique
Affinity purification Protein A
Specificity

ab190653 detects recombinant SEBOV GP (modified) and GP expressed in virus-like particles (VLP). It cross reacts to Zaire Ebola Virus (ZEBOV) GP expressed in VLP. A very slight cross-reactivity to Marburg virus (MARV) may also be observed. Cross reactivity to the HA epitope tag of the immunogen may also be observed.

Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

SEBOV GP also known as Sudan ebolavirus glycoprotein functions mechanically as a structural protein on the virus surface facilitating entry into host cells. This glycoprotein weighs approximately 64 kDa and is expressed on the virion envelope. It mediates attachment to host cells by binding to cellular receptors initiating the endocytosis process necessary for viral infection. SEBOV GP’s trimeric structure plays an important role during membrane fusion after the virus is taken into the host cell's endosome.

Biological function summary

SEBOV GP enables the Sudan strain of the ebolavirus to evade the host's immune response. The protein is part of a larger complex formed with other viral proteins such as VP40 and VP30 which aids in assembling and budding new viral particles from infected cells. SEBOV GP has a significant influence on pathogenesis by affecting cytokine production and causing cytopathic effects which contribute to the viral disease symptoms.

Pathways

SEBOV GP is involved in the viral infection pathway and membrane trafficking. It interacts with host proteins such as NPC1 during the fusion process after internalization. SEBOV GP indirectly associates with the interferon response pathway by modulating host immune signaling contributing to its immune evasion strategies. Through its actions this glycoprotein impacts various transcription pathways related to immune system regulation.

Associated diseases and disorders

SEBOV GP relates directly to viral hemorrhagic fevers caused by the Sudan ebolavirus. It also influences severe components of the immune response leading to multi-organ dysfunction syndrome. The glycoprotein has connections with human proteins like TIM-1 which serves as an entry co-factor important in pathogenesis. Targeting SEBOV GP with antibodies or antivirals could provide therapeutic strategies for Ebola virus disease aiming to block virus entry and replication.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image

  • Western blot - Anti-SEBOV GP antibody (ab190653), expandable thumbnail

    Western blot - Anti-SEBOV GP antibody (ab190653)

    The blot was visualized using an anti rabbit HRP conjugate and chromogenic substrate.

    GP is visualized as multiple bands representig different glycosylation patterns and GP subunits.

    All lanes: Western blot - Anti-SEBOV GP antibody (ab190653) at 5 µg/mL

    Lane 1: SEBOV VLP at 4 µg

    Lane 2: ZEBOV VLP at 4 µg

    Lane 3: MARV VLP at 4 µg

    Lane 4: rSEBOV GP-HA tag expressed in mammalian cells at 0.2 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com